JAK2 and essential thrombocythemia: Specifically, carriers of the 46/1 haplotype had a 3.7-fold increased risk of acquiring the JAK2V617F mutation [93], a higher susceptibility to acquire a JAK2 exon 12 mutation [19,94], and an increased disposition (odds ratio of 2.3) for the development of PV versus ET [85].